

**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:

Claims 1-33. (Cancelled)

34. (Withdrawn - Currently Amended) A compound, which is selected from the group consisting of:

*N*-(4-(Hydroxycarbamoyl)phenyl)-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxamide<sub>1</sub>

*N*-(4-(2-Aminophenylcarbamoyl)phenyl)-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxamide<sub>1</sub>

*N*-(1,2,3,4-Tetrahydro-1,1,4,4-tetramethylnaphthalen-6-yl)-*N*'-hydroxyterephthalamide<sub>1</sub>

4-((*E*)-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-6-yl)vinyl)-*N*-hydroxybenzamide<sub>1</sub>

4-((*Z*)-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-6-yl)vinyl)-*N*-hydroxybenzamide<sub>1</sub>

4-(2,2-difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)-*N*-hydroxybenzamide<sub>1</sub>

3-(2,2-difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)-*N*-hydroxybenzamide<sub>1</sub>

4-((2,2-difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)methyl)-*N*-hydroxybenzamide<sub>1</sub>

*N*-(4-((hydroxycarbamoyl)difluoromethyl)phenyl)-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxamide,

*N*-(4-Hydroxycarbamoyl-phenyl)-*N'*-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-oxalamide and

*N*-(4-Hydroxycarbamoyl-benzyl)-*N'*-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-oxalamide.

35. (Withdrawn - Currently Amended) A compound, which is selected from the group consisting of:

4-(2,2-Difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)-*N*-hydroxybenzamide,

*N*-(1,2,3,4-Tetrahydro-1,1,4,4-tetramethylnaphthalen-6-yl)-*N'*-hydroxyterephthalamide,

4-((2,2-Difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)methyl)-*N*-hydroxybenzamide and

*N*-(4-(Hydroxycarbamoyl)phenyl)-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxamide.

36. (Currently Amended) A pharmaceutical composition comprising at least one compound of formula (I), as defined in claim [[22]]34, and a pharmaceutically acceptable vehicle or support.

37. (Currently Amended) A method for the treatment of ~~conditions mediated by HDAC, such as cancers, in particular promyelocytic leukaemia, or other diseases associated with abnormal cell proliferation, such as psoriasis~~, comprising the

administration to a subject in need thereof of an effective amount of a compound as defined in claim 34.

38. (Currently Amended) A method for the treatment of ~~central and peripheral nervous system diseases or neurodegenerative diseases associated with an excitotoxicity, such as~~ Huntington's disease, ~~such as~~ polyglutamine expansion diseases, Alzheimer disease, Parkinson disease, multiple sclerosis, neuronal ischemia or amyotrophic lateral sclerosis (ALS), comprising the administration to a subject in need thereof of an effective amount of a compound as defined in claim 34.

39. (Previously Presented) A method for the treatment of fibrosis, comprising the administration to a subject in need thereof of an effective amount of a compound as defined in claim 34.

40. (Previously Presented) A method according to claim 37, wherein the cancer is selected from promyelocytic leukaemia, prostate cancer, ovarian cancer, pancreas cancer, lung cancer, breast cancer, liver cancer, head and neck cancer, colon cancer, bladder cancer, non-Hodgkin 's lymphoma cancer and melanoma.

41. (Previously Presented) A method for reducing cancer cell proliferation, comprising the administration to a subject in need thereof of an effective amount of a compound as defined in claim 34.

42. (new) The method of claim 37 wherein cancer is promyelocytic leukaemia.